What is HC Wainwright’s Estimate for DYAI FY2024 Earnings?

Dyadic International, Inc. (NASDAQ:DYAI) – Equities research analysts at HC Wainwright issued their FY2024 earnings estimates for Dyadic International in a research report issued to clients and investors on Wednesday, November 13th. HC Wainwright analyst V. Bernardino expects that the biotechnology company will earn ($0.15) per share for the year. HC Wainwright has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for Dyadic International’s current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Dyadic International’s Q4 2024 earnings at ($0.01) EPS and FY2025 earnings at ($0.06) EPS.

Dyadic International (NASDAQ:DYAI) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.06. Dyadic International had a negative return on equity of 149.16% and a negative net margin of 188.09%. The company had revenue of $1.96 million during the quarter, compared to analyst estimates of $1.05 million. During the same period in the previous year, the company earned ($0.06) earnings per share.

Dyadic International Price Performance

Shares of Dyadic International stock opened at $1.13 on Monday. The firm has a fifty day moving average price of $1.12 and a two-hundred day moving average price of $1.42. Dyadic International has a fifty-two week low of $0.93 and a fifty-two week high of $2.67. The company has a debt-to-equity ratio of 1.54, a current ratio of 5.15 and a quick ratio of 5.39. The company has a market cap of $33.43 million, a PE ratio of -4.91 and a beta of 0.72.

Institutional Investors Weigh In On Dyadic International

An institutional investor recently raised its position in Dyadic International stock. Chapin Davis Inc. raised its holdings in Dyadic International, Inc. (NASDAQ:DYAI) by 2.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 868,301 shares of the biotechnology company’s stock after buying an additional 21,000 shares during the quarter. Chapin Davis Inc. owned 2.97% of Dyadic International worth $903,000 as of its most recent SEC filing. 27.95% of the stock is owned by hedge funds and other institutional investors.

About Dyadic International

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.